Lv3
312 积分 2022-10-28 加入
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
10小时前
已完结
Hepatic Pseudoprogression after Treatment with Nectin-4–Targeted Antibody–Drug Conjugate
21天前
已完结
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
2个月前
已完结
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2个月前
已完结
The 21-day cumulative irritation assay in man: a half-century summary and re-evaluation
2个月前
已完结
A Reappraisal of the 21-Day Cumulative Irritation Test in Man
2个月前
已完结
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study
3个月前
已完结
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study
3个月前
已完结
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
4个月前
已完结
皖公网安备34019202002308
